Zobrazeno 1 - 10
of 234
pro vyhledávání: ''
Publikováno v:
BMC Cancer, Vol 21, Iss 1, Pp 1-6 (2021)
BMC Cancer
BMC Cancer
Background Carnitine is related to malaise, and cisplatin is associated with decreased carnitine. The purpose of this study was to elucidate the effects of one course of induction chemotherapy (IC) for head and neck cancer on blood carnitine levels,
Publikováno v:
BMC Cancer, Vol 21, Iss 1, Pp 1-8 (2021)
BMC Cancer
BMC Cancer
Background Regorafenib has shown promising results as a second-line therapy for patients with hepatocellular carcinoma (HCC) who progressed on sorafenib. Although there have been several data regarding the efficacy of sequential therapy with sorafeni
Autor:
Pi-Hung Tung, Allen Chung-Cheng Huang, Chih-Hsi Scott Kuo, Cheng-Ta Yang, Fu-Tsai Chung, Chien-Ying Liu, Yueh-Fu Fang, Chin-Chou Wang, John Wen-Cheng Chang, Yi-Ke Guo
Publikováno v:
BMC Cancer, Vol 21, Iss 1, Pp 1-8 (2021)
BMC Cancer
BMC Cancer
Background Crizotinib is the approved treatment for advanced non-small cell lung cancers (NSCLCs) of anaplastic lymphoma kinase (ALK) fusion. Failure of crizotinib treatment frequently involves drug intolerance or resistance. Comparison of using seco
Autor:
Arne Kolstad, Riikka Räty, Lavanya Lokhande, Martin Hutchings, Venera Kuci Emruli, Mats Jerkeman, Sara Ek
Publikováno v:
BMC Cancer, Vol 20, Iss 1, Pp 1-13 (2020)
BMC Cancer
BMC Cancer
Background Response to modern treatment strategies, which combine cytotoxic compounds with immune stimulatory agents and targeted treatment is highly variable among MCL patients. Thus, providing prognostic and predictive markers for risk adapted ther
Autor:
Peter M. Voorhees, Jianming He, Sarah Cote, Ravi Potluri, Mary Slavcev, Annette Lam, Eric M Maiese, Maneesha Mehra, Sandhya Nair, Jon Ukropec, Rafael Fonseca, Saad Z. Usmani
Publikováno v:
BMC Cancer, Vol 20, Iss 1, Pp 1-11 (2020)
BMC Cancer
BMC Cancer
Background For patients with multiple myeloma (MM), each additional line of therapy (LOT) is associated with lower response rates, shorter treatment duration and treatment-free intervals, and increased rates of toxicities and comorbidities. Here, we
Autor:
Ahmad Hushki, Maya Charafeddine, Clement El Khoury, Faiez Daoud, Ali Dabous, Faek R. Jamali, Mahmoud Al Masri, Ibrahim Khalifeh, Rula Amarin, Malek Kreidieh, Ali Shamseddine, Issa Mohamad, Mousa Elkhaldi, Monita Al Darazi, Rim Turfa, Kholoud Alqasem, Samer Deeba, Omar Jaber, Deborah Mukherji, Fady Geara, Joseph Kattan, Ziad El Husseini, Tala Al Awabdeh, Youssef H. Zeidan, Sally Temraz
Publikováno v:
BMC Cancer, Vol 20, Iss 1, Pp 1-11 (2020)
BMC Cancer
BMC Cancer
Background Current standard practice for locally advanced rectal cancer (LARC) entails a multidisciplinary approach that includes preoperative chemoradiotherapy, followed by total mesorectal excision, and then adjuvant chemotherapy. The latter has be
Autor:
Cindy Weinstein, S. Khanani, Elizabeth Beckford-Brathwaite, Karin Jordan, Stuart A. Green, Waldimir Vallejos, Annpey Pong, Stephen J. Noga, Bernardo Leon Rapoport
Publikováno v:
BMC Cancer, Vol 20, Iss 1, Pp 1-10 (2020)
BMC Cancer
BMC Cancer
Background Results from a phase III, randomized, double-blind, active comparator-controlled, parallel-group trial evaluating fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting (CINV) found that a single-day, triple-antiemeti
Publikováno v:
BMC Cancer, Vol 20, Iss 1, Pp 1-9 (2020)
BMC Cancer
BMC Cancer
Background The study aimed to investigate the clinical features and prognosis factors of adult patients with Langerhans cell histiocytosis (LCH) with pulmonary involvement, especially multisystem (MS) LCH with pulmonary involvement. Methods We retros
Autor:
Lorenzo Antonuzzo, Carmine Pinto, Guglielmo Nasti, Alessandra Romagnani, Roberto Bordonaro, Francesco Iachetta, Giuseppe Tonini, Evaristo Maiello, Angela Damato, Alberto Zaniboni, Annalisa Berselli, Nicola Normanno, Francesca Bergamo
Publikováno v:
BMC Cancer, Vol 20, Iss 1, Pp 1-10 (2020)
BMC Cancer
BMC Cancer
Background FOLFOXIRI (fluorouracil, leucovorin, oxaliplatin, and irinotecan) plus bevacizumab has shown to be one of the therapeutic regimens in first line with the highest activity in patients (pts.) with metastatic colorectal cancer (mCRC) unselect
Autor:
Hee Kyung Ahn, Eun Joo Kang, Seong Hoon Shin, Sung-Bae Kim, Y. Lee, Keon Uk Park, Jung Hye Kwon, Kyoung Eun Lee, Keun Wook Lee, Hwan Jung Yun, Hye Ryun Kim, Min Kyoung Kim, Jin-Soo Kim, Jin-Hyuk Choi, Bhumsuk Keam
Publikováno v:
BMC Cancer, Vol 20, Iss 1, Pp 1-9 (2020)
BMC Cancer
BMC Cancer
Background By investigating treatment patterns and outcomes in locally advanced head and neck squamous cell carcinoma (LA-HNSCC), we aimed at providing valuable insights into the optimal therapeutic strategy for physicians in real-world practice. Met